T-cell based immunotherapy is certainly one of the greatest breakthroughs in recent cancer treatment history, providing hope to millions of patients across the world. Thanks to research under the TIPC_TIL_IP project, pancreatic cancer patients could benefit from this treatment within the next five years.
First discovered for human skin melanoma, the therapeutic potential of tumour-specific T-cells – commonly referred to as T-cell immunotherapy – is tremendous. Reprogrammed T-cells can effectively target the somatic mutations contained in tumour-specific genomic DNA encoding peptide antigens, which means that other types of cancer carrying these somatic mutations, such as lung cancer, are also sensitive to this form of treatment.
Further details: T-cell immunotherapy becomes a viable option for pancreatic cancer patients